|
29 Nov 2019 |
Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
|
|
27 Nov 2019 |
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-PD-1/HER2 Bispecific Antibody in China
|
|
26 Nov 2019 |
Immunovant Initiates Dosing in ASCEND-GO 2, a Phase 2b Trial of IMVT-1401 in Patients with Graves’ Ophthalmopathy (GO)
|
|
26 Nov 2019 |
Celltrion Healthcare receives EU marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima SC™, for the treatment of people with rheumatoid arthritis
|
|
25 Nov 2019 |
First China-manufactured Trastuzumab Biosimilar HLX02 Global Phase III Trial Met Primary Endpoint in Breast Cancer
|
|
23 Nov 2019 |
Genentech Presents Pivotal Data Demonstrating Tecentriq in Combination With Avastin Improves Overall Survival in People With the Most Common Form of Liver Cancer
|
|
21 Nov 2019 |
CytoDyn Reports Strong Positive Preclinical Data to Demonstrate Potential of Leronlimab in Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Humanized Mouse Model
|
|
20 Nov 2019 |
Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis
|
|
20 Nov 2019 |
European Commission Approves Two New Regimens of Merck’s KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
|
|
20 Nov 2019 |
Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1
|
|
19 Nov 2019 |
Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy
|
|
19 Nov 2019 |
Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
|
|
19 Nov 2019 |
MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis
|
|
19 Nov 2019 |
Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day
|
|
19 Nov 2019 |
Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159
|
|
19 Nov 2019 |
FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions
|
|
18 Nov 2019 |
3SBio Selects Verseau's PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration
|
|
18 Nov 2019 |
Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack
|
|
16 Nov 2019 |
CHMP recommends conditional EU approval of Roche’s Polivy for people with previously treated aggressive lymphoma
|
|
16 Nov 2019 |
CHMP recommends EU approval of Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
|
|
16 Nov 2019 |
RemeGen, Ltd. Announces Positive Results from Phase IIb Clinical Trial in Systemic Lupus Erythematosus
|
|
16 Nov 2019 |
New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
|
|
15 Nov 2019 |
Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
|
|
14 Nov 2019 |
Translational Research in Oncology (TRIO) Initiates Phase I Study for MT-5111
|
|
13 Nov 2019 |
Nucala (mepolizumab) is the first treatment to show a significant reduction in flares for patients with Hypereosinophilic Syndrome (HES)
|
